Good afternoon and welcome to Markets Desk.
The global bond selloff is deepening, and Asian markets are at the center of it. Japanese and Australian sovereign yields climbed sharply overnight, adding to pressure on global fixed income even as Brent crude edged lower. The divergence between falling energy prices and rising debt costs signals that inflation expectations and fiscal concerns are driving this move, not commodity demand.
Turning to equities, Sweetgreen is one of the more interesting recovery stories on the tape right now. The fast-casual chain is up thirty-two percent since the cyclospora outbreak that forced it to slash guidance earlier this year. With that headwind fully cleared, the question investors are asking is whether the valuation has gotten ahead of the fundamental recovery or whether there is still a credible growth case to be made here.
And in biotech, Monte Rosa Therapeutics is catching a bid today as the company prepares to release Phase one clinical data from its GFORCE-one study of MRT-eight-one-oh-two, a molecular glue degrader targeting elevated cardiovascular disease risk. Early-stage data readouts are binary by nature, so the move higher ahead of the print reflects genuine anticipation rather than confirmed results.
That's the tape. Markets Desk, signing off the floor.
